CHEMIN DES MINES 9, GENEVA, V8
Spin-Out Neurosterix Completes Phase 1 Clinical Studies of NTX-253 for Schizophrenia
Announces Executive Management Changes
Reports 2026 Half-Year Results and Provides Corporate Update
Regains Rights to GABAB Positive Allosteric Modulator Portfolio
Raises USD 2.8 million through its ATM agreement and extends cash runway to the fourth quarter 2027
Announces Publication of Research Highlighting Therapeutic Potential of mGlu7 Modulation in Regulating Sleep and Wakefulness
Shareholders Approve All Resolutions at Annual General Meeting
Convenes Annual General Meeting 2026
Annual and Transition Report of Foreign Private Issuers
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities of Certain Foreign Private Issuers and Certain Canadian Issuers, Offered on a Continuous Basis
Prospectus filed pursuant to Rule 424(b)(3)
No filings found
Statement of Changes in Beneficial Ownership
NT 20-F
Post-Effective Amendment to Registration Statement
Post-Effective Amendment to a Registration Statement for Depositary Shares
Correspondence